Effects of anlotinib combined with camrelizumab and chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma on tumor immune microenvironment.

ABSTRACT:

Background

Esophageal squamous cell carcinoma (ESCC) presents significant therapeutic challenges due to limited treatment options. While immune checkpoint inhibitors (ICIs) combined with chemotherapy have demonstrated efficacy, variable response rates underscore the necessity for enhanced therapeutic approaches. Anlotinib, a multi-target tyrosine kinase inhibitor, has shown synergistic effects with ICIs in clinical practice. However, its influence on the tumor immune microenvironment (TIME) in ESCC requires further elucidation. This study aimed to investigate anlotinib's effects on the TIME.

Methods

In our phase II trial (NCT04471480), we analyzed 8 advanced ESCC patients who achieved operability following treatment with anlotinib, camrelizumab, and chemotherapy (TCAC group)

SUBMITTER: Xu M 

PROVIDER: S-EPMC12432929 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature